Logo

Sanofi's Avalglucosidase alfa Receives CHMP's Positive Opinion for Patients with Pompe Disease

Share this

Sanofi's Avalglucosidase alfa Receives CHMP's Positive Opinion for Patients with Pompe Disease

Shots:

  • The CHMP’s positive opinion is based on P-III COMET study assessing avalglucosidase alfa that demonstrated improvements in respiratory function & movement endurance measures in people with late-onset Pompe disease
  • The CHMP concluded that avalglucosidase alfa does not qualify as a New Active Substance (NAS). Sanofi will be requesting a re-examination of the CHMP’s opinion related to the NAS conclusion
  • The CHMP’s positive opinion follows the EMA’s acceptance of MAA for the therapy at the end of 2020. Avalglucosidase alfa is an enzyme replacement therapy targeting M6P receptor and is currently under review in multiple countries including the US- UK & Japan

  | Ref: Sanofi | Image: Pharmaceutical Technology

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions